Best Weight-Loss Medications for Women in Menopause: 6 Options Ranked

Tirzepatide (Zepbound) has the biggest weight loss on record for women at every stage of menopause, with semaglutide as a weekly shot (Wegovy) or a daily pill close behind. In a reanalysis of the big tirzepatide trial, postmenopausal women on the top dose lost about 23% of their weight compared with 3% on placebo (Tchang 2025, Obesity). Older pills such as phentermine-topiramate and naltrexone-bupropion work, but produce roughly half that loss. Hormone therapy does not treat weight on its own, though early data suggest women who use it alongside a GLP-1 lose more.

How we chose

We ranked each option on four things, checked on September 30, 2026:

• Size of the weight loss in large randomized trials, the kind where neither patient nor doctor knows who got the real drug.
• Proof in women at midlife, meaning data broken out by menopause stage, not only mixed groups.
• FDA status for chronic weight management.
• Side effects and who should skip it, from the FDA label.

1. Tirzepatide (Zepbound)

Tirzepatide is a weekly shot that copies two gut hormones (GLP-1 and GIP) that tell your brain you are full and help your body handle sugar. It is FDA-approved for chronic weight management (Zepbound label, DailyMed).

In the main trial of 2,539 adults without diabetes, people on the 15 mg dose lost 20.9% of their body weight over 72 weeks, compared with 3.1% on placebo (SURMOUNT-1, NEJM 2022). When researchers later split the women in that trial by menopause stage, the results held: about 23% loss in perimenopausal and postmenopausal women versus 3% on placebo, with waists shrinking about 20 cm. Between 97% and 98% of women on tirzepatide lost at least 5% of their weight (Tchang 2025, Obesity). That reanalysis was run by the drugmaker and looked back at existing data, so treat it as strong support, not a separate trial.

Best for: women who want the largest average loss and are fine with a weekly injection.

Trade-offs: nausea, diarrhea and constipation are common, mostly while the dose climbs. In the main trial, 6% to 7% of people on the two higher doses stopped because of side effects (SURMOUNT-1, NEJM 2022). The label carries a boxed warning about thyroid C-cell tumors seen in rodents, so it is not for women with a personal or family history of medullary thyroid cancer or MEN 2 (Zepbound label, DailyMed).

2. Semaglutide injection (Wegovy)

Semaglutide copies GLP-1 alone. As a weekly shot it is FDA-approved for weight management and for lowering heart attack and stroke risk in people with heart disease (Wegovy label, DailyMed).

In the first large trial, 1,961 adults lost 14.9% of their weight over 68 weeks on semaglutide 2.4 mg, compared with 2.4% on placebo. Half lost 15% or more (STEP 1, NEJM 2021). For a direct comparison between the two weekly shots, see our tirzepatide vs semaglutide breakdown.

Best for: women who want a well-studied weekly shot with heart-protection data, or who did not tolerate tirzepatide.

Trade-offs: slightly less average loss than tirzepatide. Nausea and diarrhea were the most common side effects, and 4.5% stopped because of stomach problems (STEP 1, NEJM 2021). Same thyroid boxed warning as tirzepatide (Wegovy label, DailyMed).

3. Oral semaglutide 25 mg (Wegovy pill)

This is the same drug as the Wegovy shot in a once-daily tablet. The FDA approved it for weight management in December 2025 (FDA approval letter, NDA 218316).

In a 64-week trial of 307 adults, the pill group lost 13.6% of their weight compared with 2.2% on placebo (OASIS 4, NEJM 2025). That is close to the injection's result in a smaller study.

Best for: women who want GLP-1 results without needles.

Trade-offs: you take it every day on an empty stomach, and stomach side effects were common: 74% on the pill reported at least one versus 42% on placebo (OASIS 4, NEJM 2025). The trial was much smaller than the injection trials, and there is no menopause-specific breakdown yet.

4. Phentermine-topiramate (Qsymia)

This daily capsule pairs an appetite suppressor (phentermine) with a seizure and migraine drug (topiramate) that also cuts cravings. It has been FDA-approved for weight management since 2012 (Qsymia label, DailyMed).

In a 56-week trial of 2,487 adults with weight-related health problems, the top dose produced 9.8% weight loss compared with 1.2% on placebo (CONQUER, Lancet 2011).

Best for: women who cannot take a GLP-1 or prefer a daily capsule with a long track record.

Trade-offs: about half the loss of the GLP-1s. Dry mouth, tingling, constipation, insomnia and changes in taste were common at the top dose (CONQUER, Lancet 2011). It is not for women with glaucoma, an overactive thyroid, or who recently took an MAO inhibitor (Qsymia label, DailyMed).

5. Naltrexone-bupropion (Contrave)

This daily tablet combines an addiction drug (naltrexone) with an antidepressant (bupropion) to quiet food cravings (Contrave label, DailyMed).

In a 56-week trial of 1,742 adults, the full dose produced 6.1% weight loss compared with 1.3% on placebo. Only half of participants finished the full year (COR-I, Lancet 2010).

Best for: women whose main problem is cravings or emotional eating, who cannot use other options.

Trade-offs: the smallest loss on this list. Nausea hit about 30% of users (COR-I, Lancet 2010). It carries a boxed warning about suicidal thoughts because it contains an antidepressant, and it is not for women with seizure disorders (Contrave label, DailyMed).

6. Menopause hormone therapy, alongside a GLP-1

Hormone therapy (estrogen, with progesterone if you have a uterus) treats hot flashes, night sweats and vaginal dryness. On its own it is not a weight-loss drug. Studies show it either has no effect on weight or slightly slows midlife weight gain and waist growth (Menopause Society 2022 position statement).

Two Mayo Clinic record reviews suggest it may help a GLP-1 work better. Among 106 postmenopausal women on semaglutide, the 16 also using hormone therapy lost 16% at one year versus 12% for those not using it (Hurtado 2024, Menopause). Among 120 women on tirzepatide, hormone therapy users lost 17% versus 14%, and 45% of them passed 20% loss versus 18% of non-users (Endocrine Society, ENDO 2025). These studies looked back at medical records, so other differences between the women could explain part of the gap. More on starting it in our hormone therapy guide.

Best for: women who also have menopause symptoms and are good candidates for hormone therapy anyway.

Trade-offs: not an option for women with certain cancers, clots or liver disease, and it will not move the scale on its own.

Comparison at a glance

How to choose

Start with your goal and your history. If you want the most loss and can do a weekly shot, tirzepatide leads. If needles are a deal-breaker, the semaglutide pill gets you close. If hot flashes and poor sleep are part of the picture, ask about hormone therapy too, since symptom relief and better GLP-1 results may come together. Our guide to what to expect from a GLP-1 in perimenopause covers timelines.

Your thyroid history, mood history, eye pressure and blood pressure decide which of these are safe for you. To get a plan matched to your goals and health history, take the HOD quiz.